Selective Regeneration

How Surrozen is targeting specific Wnt receptors to regenerate select tissues

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members of the highly interrelated Wnt receptor family. The biotech is focusing first on bone and liver regeneration.

Wnts, or wingless-type MMTV integration site proteins, are a class of secreted molecules that help drive embryonic development and, later in

Read the full 723 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE